Grant: Discovery Grants Program - Individual
University of Guelph
$56,000.00
Antibody-based bacterial cytotoxicity mediated by mechanisms independent of CDC and ADCC
FY 2013-14
Summary
In addition to their well-characterized functions of antigen recognition for destruction of specific targets through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), numerous antibodies, termed Abzymes, have been found to possess catalytic abilities such as hydrolysis of nucleotides, proteins, and polysaccharides, phosphorylation of proteins and lipids, and generation of free radicals. We have found that a monoclonal antibody (mAb), namely anti-Pseudomonas aeruginosa O6ad lipopolysaccaride (LPS) IgG1, and its recombinant antibody (rAb) fragments (Fab and scFv) exhibit cytotoxic activities against their specific target bacterium independent of ADCC and CDC. Our preliminary unpublished data indicate that this mAb has co-evolved two functions onto one molecule: specific binding to the surface of a pathogen, and the ability to kill it per se. We propose a five-year research program to test the hypothesis that this mAb and its fragments are catalytic in nature, and to elucidate the specific killing mechanism through experimentation involving biochemical, molecular, physiological, structural, analytic, immunological, genetic, and pharmacological techniques. We will also search for other antibodies with specific bactericidal characteristics, and to compare killing mechanisms for further understanding of this phenomenon. It is anticipated that research outcomes will result in greater understanding a novel mechanism of cytotoxicity with tremendous potential for further development of applications in medicine and health.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
2243-2009
Name nom
Hall, JChristopher
Department département
Environmental Sciences, School of
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2009
Award amount
56000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Immunology
Research subject fr
Immunologie
Partie
5
Nb partie
5
Application title
Antibody-based bacterial cytotoxicity mediated by mechanisms independent of CDC and ADCC
Keyword
NSERC
Application summary
In addition to their well-characterized functions of antigen recognition for destruction of specific targets through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), numerous antibodies, termed Abzymes, have been found to possess catalytic abilities such as hydrolysis of nucleotides, proteins, and polysaccharides, phosphorylation of proteins and lipids, and generation of free radicals. We have found that a monoclonal antibody (mAb), namely anti-Pseudomonas aeruginosa O6ad lipopolysaccaride (LPS) IgG1, and its recombinant antibody (rAb) fragments (Fab and scFv) exhibit cytotoxic activities against their specific target bacterium independent of ADCC and CDC. Our preliminary unpublished data indicate that this mAb has co-evolved two functions onto one molecule: specific binding to the surface of a pathogen, and the ability to kill it per se. We propose a five-year research program to test the hypothesis that this mAb and its fragments are catalytic in nature, and to elucidate the specific killing mechanism through experimentation involving biochemical, molecular, physiological, structural, analytic, immunological, genetic, and pharmacological techniques. We will also search for other antibodies with specific bactericidal characteristics, and to compare killing mechanisms for further understanding of this phenomenon. It is anticipated that research outcomes will result in greater understanding a novel mechanism of cytotoxicity with tremendous potential for further development of applications in medicine and health.